Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Astellas Pharma US Inc. Stories

2010-07-02 07:00:00

MORRISTOWN, N.J., July 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules. Watson intends to begin shipping the product immediately. Prograf ® 5 mg had total U.S....

2010-06-07 08:00:00

CHICAGO, June 7 /PRNewswire/ -- If an average day begins as a hectic race to get the kids off to school and get to work on time, imagine starting that day with a migraine. For many of the nation's 30 million migraine sufferers whose lives are often turned upside down by their migraines, relief can't come soon enough. In a new survey released today by the National Headache Foundation (NHF), 3 in 4 migraine sufferers said their current medication doesn't work fast enough to get them back to...

2010-05-16 19:20:00

TOKYO and MELVILLE, N.Y. May 16 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI. Under the terms of...

2010-05-03 09:30:00

DEERFIELD, Ill., May 3 /PRNewswire/ -- Today Astellas Pharma US, Inc. ("Astellas") announced the launch of "Science WoRx," a program designed to help science teachers inspire the next generation of scientists. The program features a hands-on education and mentoring program, an online resource portal and online networking communities. In addition, Science WoRx is hosting a competition, "Make My LabWoRx," inviting science teachers to submit their favorite original lesson plans for a chance...

2010-04-23 03:44:00

TOKYO, April 23 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) to 5:00 p.m. New York City time on Monday, May 17, 2010, unless further extended. The tender offer was previously set to expire at 12:00 midnight New York City time on Friday, April 23, 2010....

2010-04-14 17:31:00

SAN FRANCISCO and TOKYO, April 14 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced publication of positive results from their previously reported Phase 1-2 trial of the novel triple-acting oral androgen receptor antagonist MDV3100 in men with progressive, metastatic castration-resistant prostate cancer in the April 15 online version of The Lancet. According to the published results, MDV3100 demonstrated anti-tumor activity in patients with...

2010-04-05 07:08:00

RICHMOND, Va., April 5 /PRNewswire/ -- According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have their organs and tissue donated after their deaths. While an improvement over findings from a similar survey last year in which 50 percent reported the same, the statistic illustrates a critical need to continue to increase the level of support for organ donation to save the lives of the more than 105,000 adults and children on the...

19c8d38c863a748625657985fea64fbb
2010-04-05 07:20:00

Survey reveals pervasive donation myths According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have their organs and tissue donated after their deaths. While an improvement over findings from a similar survey last year in which 50 percent reported the same, the statistic illustrates a critical need to continue to increase the level of support for organ donation to save the lives of the more than 105,000 adults and children on the...

2010-03-02 07:00:00

TOKYO, March 2 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, today announced that its indirect subsidiary, Ruby Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of OSI Pharmaceuticals (Nasdaq: OSIP) for $52.00 per share in cash. The offer and withdrawal rights are scheduled to expire at 12:00 midnight New York City time on March 31, 2010, unless the offer is extended. The Company also...

2009-10-28 15:58:00

NASDAQ: CRME TSX: COM VANCOUVER and DEERFIELD, IL, Oct. 28 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm. The ACT 5 trial,...